SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, today announced that Lyn Baranowski, chief executive officer of Avalyn, will provide a corporate overview and be available for 1x1 meetings at three upcoming investor conferences:

Oppenheimer Private Company Showcase
Presentation: Wednesday, October 11, 2023, at 10:30 a.m. ET
Location: The Intercontinental New York Barclay

BMO Life Science Private Company Showcase
Presentation: Thursday, October 12, 2023, at 1:35 p.m. ET
Location: Goodwin, The New York Times Building

2023 BofA Healthcare Trailblazers Private Company Conference
Participation: Thursday, October 26, 2023
Location: Encore Boston Harbor

About Avalyn Pharma
Avalyn is a biopharmaceutical company developing targeted therapeutics for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies. For more information, please visit avalynpharma.com.

Contacts:
Alex Straus
THRUST Strategic Communications
alex@thrustsc.com

Cara Mayfield
THRUST Strategic Communications
cara@thrustsc.com